Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.

(Aryloxopropenyl)pyrrolyl hydroxamates were recently reported by us as first examples of class II-selective HDAC inhibitors and can be useful tools to probe the biology of such enzymes. Molecular modelling and 3-D QSAR studies have been performed on a series of 25 (aryloxopropenyl)pyrrolyl hydroxamates to gain insights about their activity and selectivity against both maize HD1-B and HD1-A, two enzymes homologous of mammalian class I and class II HDACs, respectively. The studies have been accomplished by calculating alignment-independent descriptors (GRIND descriptors) using the ALMOND software. Highly descriptive and predictive 3-D QSAR models were obtained using either class I or class II inhibitory activity displaying r(2)/q(2) values of 0.96/0.81 and 0.98/0.85 for HD1-B and HD1-A, respectively. A deeper inspection revealed that in general a bent molecular shape structure is a prerequisite for HD1-A-selective inhibitory activity, while straight shape molecular skeleton leads to selective HD1-B compounds. The same conclusions could be achieved by molecular docking studies of the most selective inhibitors.

[1]  M. Guenther,et al.  Biochemical isolation and analysis of a nuclear receptor corepressor complex. , 2003, Methods in enzymology.

[2]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[3]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[4]  Silvio Massa,et al.  Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. , 2002, Journal of medicinal chemistry.

[5]  A. Mai,et al.  3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. , 2004, Journal of medicinal chemistry.

[6]  Yukihiro Itoh,et al.  Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. , 2006, Journal of medicinal chemistry.

[7]  Ishihara,et al.  Search for new charged leptons decaying into massive neutrinos and new stable charged leptons in e+e- collisions. , 1988, Physical review letters.

[8]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[9]  G. Brosch,et al.  Purification of histone deacetylase HD1‐A of germinating maize embryos , 1996, FEBS letters.

[10]  Silvio Massa,et al.  3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. , 2003, Journal of medicinal chemistry.

[11]  W. Helliger,et al.  Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. , 1999, Biochemistry.

[12]  G. Brosch,et al.  Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein. , 1997, Science.

[13]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Glaser,et al.  Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.

[15]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[16]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[17]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[19]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[20]  A. Eberharter,et al.  A comparative study of histone deacetylases of plant, fungal and vertebrate cells. , 1996, Biochimica et biophysica acta.

[21]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[22]  S. Horinouchi,et al.  In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.

[23]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[24]  A. Mai,et al.  A NEW FACILE AND EXPEDITIOUS SYNTHESIS OF N-HYDROXY-N′-PHENYLOCTANEDIAMJDE, A POTENT INDUCER OF TERMINAL CYTODIFFERECNTIATION , 2001 .

[25]  G. Brosch,et al.  Biochemical methods for analysis of histone deacetylases. , 1998, Methods.

[26]  H. Lindner,et al.  Specificity of Zea mays histone deacetylase is regulated by phosphorylation. , 1992, The Journal of biological chemistry.

[27]  Ismael Zamora,et al.  Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors , 2002, J. Comput. Aided Mol. Des..

[28]  Silvio Massa,et al.  Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.

[29]  A. Mai,et al.  Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. , 2003, Journal of medicinal chemistry.

[30]  G. Brosch,et al.  Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. , 1996, Biochemistry.

[31]  L. Guarente,et al.  The Sir2 family of protein deacetylases. , 2004, Annual review of biochemistry.

[32]  J. Walton,et al.  RPD3-type histone deacetylases in maize embryos. , 2000, Biochemistry.

[33]  Silvio Massa,et al.  3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity† , 2004 .

[34]  O. Wiest,et al.  On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. , 2004, Journal of medicinal chemistry.

[35]  Ferran Sanz,et al.  Incorporating molecular shape into the alignment-free Grid-Independent Descriptors. , 2004, Journal of medicinal chemistry.

[36]  A. Mai,et al.  3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. , 2001, Journal of medicinal chemistry.

[37]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[38]  T. Yao,et al.  Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10* , 2002, The Journal of Biological Chemistry.

[39]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[40]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[41]  L. Altucci,et al.  Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.

[42]  D. Condorelli,et al.  Structure-based rationalization of antitumor drugs mechanism of action by a MIF approach. , 2004, European journal of medicinal chemistry.